NEWS
SHL Medical | 2019.01

SHL to Showcase Innovative Solutions for High Volume Drug Delivery at Pharmapack Europe

SHL Group is looking forward to exhibiting at the 2019 Pharmapack, Europe's dedicated pharmaceutical packaging and drug delivery event from February 6-7 in Paris, France.

At the center of this year's exhibition is Molly® 2.25, SHL's high volume variation of its classic Molly® auto injector, designed with a preconfigured technology to help pharmaceutical companies minimize initial equipment investments and speed up development timelines. Boasting an intuitive design that meets a variety of patient handling profiles, Molly® 2.25 supports the trend for injection volumes in the 1-2.25mL range to meet the increasing need for the simple delivery of larger doses. SHL is also looking forward the market introduction of the first drug product based on the Molly® 2.25 program.

Another highlight at this year's event is the range of auto injectors built with SHL's Needle Isolation Technology (NIT®). This proprietary technology allows cartridge-based injection devices to be built as easy-to-use auto injectors with permanently hidden needles. “The NIT® is a true problem solver because cartridges not only open up a world of opportunities for pharma companies, it also offers patients a safe and intuitive experience without sacrificing usability,” said Magnus Fastmarken, SHL's global director of marketing.

This year, SHL is again pairing up with Innovation Zed to present InsulCheck at Pharmapack's Innovation Gallery. This year's display, InsulCheck Connect, is a smart pen injector add-on that displays the time elapsed since last injection. It can be connected to 3rd party service applications to track insulin injection. InsulCheck Connect is compatible with a *variety of existing insulin injection pens on the market and can be customized to support other pen injector projects.

Visitors are invited to explore SHL's innovative injectable drug delivery solutions at Stand B44 at the Paris Expo Porte de Versailles.

*For full list of pen injectors compatible with InsulCheck Connect, please refer to the company website, or contact us at info@shl-group.com.)

關於瑞健

瑞健集團為領航全球先進藥物輸送系統產業的設計、研發、及製造龍頭。其事業據點涵蓋位於瑞士、瑞典、美國及台灣的現代化設計中心以及設立於亞洲的先進製造廠房。 瑞健主要客戶為世界知名藥廠以及生技公司,提供如自動化注射器,筆型注射器以及吸入器等高科技產品。瑞健持續投資於研發製造為開發新型高科技藥物輸送系統以符合市場趨勢,其中包括使用步驟簡化、注射器精密化、拋棄式/複用式多重選擇、劑量彈性化以及藥劑濃稠度之配合等。

瑞健目前全球已有超過 4,000 名員工,主要分為以下事業群:

SHL Medical 主要為製藥和生技企業設計、研發、及製造高科技藥物傳輸系統,也提供終端組裝、醫材標籤及包裝相關服務

SHL Healthcare 從事居家及醫院護理器材之研發製造

SHL Technologies 提供醫療科技及工業設備之 OEM 製造與相關服務

如欲更深入了解瑞健集團,請至公司網站 www.shl.group.

瑞健媒體聯絡人

info@shl-group.com